false 0000880242 0000880242 2024-06-13 2024-06-13
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported): June 13, 2024
 
BioLargo, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
  
000-19709
  
65-0159115
(State or other jurisdiction
of incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)
 
 
14921 Chestnut St., Westminster, California
  
92683
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (888) 400-2863
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
BLGO
OTCQB
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 5.07          Submission of Matters to a Vote of Security Holders
 
BioLargo, Inc. (the “Company”) held its 2024 annual stockholder meeting on June 13, 2024. The following proposals were each submitted to a vote of stockholders through the solicitation of proxies or otherwise:
 
 
1.
A proposal to elect the following seven individuals to the Company’s Board of Directors: Dennis P. Calvert, Kenneth R. Code, Dennis E. Marshall, Joseph L. Provenzano, Jack B. Strommen, Linda Park, and Christina Bray;
 
 
2.
A proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers;
 
 
3.
A proposal to ratify the appointment of Hacker Johnson & Smith PA as the Company's independent registered public accounting firm for the year ending December 31, 2024; and
 
 
4.
A proposal to adopt the 2024 Equity Incentive Plan.
 
A quorum was present in person or by proxy. There were no director nominees other than as set forth above. Each director was elected to the Company’s Board of Directors, and each of proposals 2, 3 and 4 were approved, in accordance with Delaware law and the Company’s bylaws. The voting results are as follows:
 
 
Proposal One
 
Votes For
Votes Withheld
Broker Non-Vote
 Dennis P. Calvert
95,973,191
              2,531,303
            75,196,191
 Kenneth R. Code
97,016,500
              1,487,994
            75,196,191
Dennis E. Marshall
96,713,705
              1,790,789
            75,196,191
Joseph L. Provenzano
96,906,120
              1,598,374
            75,196,191
Jack B. Strommen
96,916,500
              1,587,994
            75,196,191
Linda Park
96,928,400
              1,576,094
            75,196,191
Christina Bray
96,800,400
              1,704,094
            75,196,191
 
Proposals 2 - 4
 Votes For
 Votes Against
 Votes Abstain
 Broker Non-Vote
 Percentage
"for"
2
     94,165,357
              3,453,224
                885,913
             75,196,191
96.5%
3
   170,877,497
              1,891,556
                931,632
                          -
98.9%
4
   170,877,497
              1,891,556
                931,632
                          -
98.9%
 
 
For the proposals to approve, on an advisory basis, the compensation of the Company’s named executive officers, prior year votes are as follows:
 
Year
Votes For
Votes Against
Votes Abstain
Broker Non-Vote
2020
          72,180,828
                      2,950,599
                     1,752,675
                      47,142,003
2021
          87,066,389
                      3,646,737
                     2,462,756
                      43,453,003
2022
          84,305,241
                      9,841,157
                     2,175,747
                      57,328,090
2023
          76,470,107
                      5,477,240
                     2,816,330
                      74,462,248
 
 
 
 
Item 9.01. Financial Statements and Exhibits.
 
(d)         Exhibits.
 
   
Exhibit
No.
Description
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
                 
Date: June 20, 2024
      
BIOLARGO, INC.
         
           
By:
  
/s/ Dennis P. Calvert
               
Dennis P. Calvert
               
President and Chief Executive Officer